Dailymirror.news,Hyderabad, December 1,2025: SAI Parenteral’s Limited (SPL), a diversified pharmaceutical formulations company, has announced the acquisition of a 74.6% controlling stake in Adelaide-based Noumed Pharmaceuticals Pty Ltd for a total consideration of ₹125 crore. The move marks a major strategic step for SPL as it expands its global footprint and strengthens its capabilities in regulated and semi-regulated markets.

SPL, which filed its Draft Red Herring Prospectus (DRHP) with SEBI on September 30, 2025, plans to raise up to ₹285 crore through a fresh issue and facilitate an offer for sale (OFS) of up to 35 lakh equity shares by existing shareholders.

Noumed Pharmaceuticals, with annual revenues of AUD 60 million, is a prominent supplier of private-label over-the-counter (OTC) products to leading pharmacy chains across Australia and New Zealand. The company is currently investing AUD 53 million to set up a world-class manufacturing facility in Adelaide, expected to commence commercial operations in Q4 of CY 2026. With a vast portfolio of 451+ product dossiers, Noumed offers strong coverage across diverse therapeutic areas.

Leadership Speaks

Anil KK, Managing Director, SAI Parenteral’s Limited, described the acquisition as a “pivotal and transformative milestone” for the company.

“By integrating Noumed’s R&D expertise, distribution network, dossier library, and upcoming manufacturing facility with SAI Parenteral’s strengths in India, we are unlocking strong synergies across the value chain. This partnership significantly enhances our entry into regulated and semi-regulated markets with a broader, more competitive product portfolio,” he said.

“The acquisition also enables us to leverage Noumed’s longstanding customer relationships and supply contracts, improving revenue quality and visibility as we expand globally.”

Mark Thulborne, Managing Director, Noumed Pharmaceuticals Pty Ltd, expressed confidence in the partnership.

“We are excited to formalize this collaboration. Having worked closely with SAI Parenteral’s, we believe this synergy will accelerate our product pipeline, enhance manufacturing strengths, and meet growing demand across Australia, New Zealand, and international markets. Together, we look forward to creating long-term value for all stakeholders.”

SAI Parenteral’s is backed by marquee investors including Samarsh Capital, Vyom Partners, Blue Lotus Capital, and Gruhas, further strengthening its position as it scales its global operations.